Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype

Cancer Research

Volumn 69, Issue 7, 2009, Pages 2981-2989

  Balliet, Renee M ^a,b   Chen, Gang ^a,b   Gallagher, Caria J ^a,b   Dellinger, Ryan W ^a,b   Sun, Dongxiao ^a,b   Lazarusw, Philip ^a,b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; VORINOSTAT; ENZYME INHIBITOR; HYDROXAMIC ACID;

ARTICLE; CELL FREE SYSTEM; CELL STRAIN HEK293; ENZYME ACTIVITY; ENZYME METABOLISM; GENE DELETION; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; HOMOGENATE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KINETICS; LIVER MICROSOME; PHENOTYPE; PRIORITY JOURNAL; WILD TYPE; CELL LINE; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MISSENSE MUTATION; SITE DIRECTED MUTAGENESIS;

CELL LINE; ENZYME INHIBITORS; GLUCURONOSYLTRANSFERASE; HUMANS; HYDROXAMIC ACIDS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 66149089601     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4143     Document Type: Article

References (55)

1. Dokmanovic M1 Clarke C1 Marks PA. Histone deace- tylase inhibitors: overview and perspectives. MoI Cancer Res 2007;5:981-989.
2. Khan N1 Jeffers M1 Kumar S1 et al. Determination, of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. BiochemJ 2008;409:581-589.
3. Mann BS1 Johnson JR1 Cohen MH1 Justice R1 Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-ce11 lymphoma. Oncologist 2007;12:1247-1252.
4. Rasheed W1 Bishton M, Johnstone RW1 Prince HM. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 2008;8:413-432.
5. Rubin EH1 Agrawal NG1 Friedman EJ1 et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 2006: 12:7039-7045.
6. Du L1 Musson DG1 Wang AQ. High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum. Rapid Commun Mass Spectrom 2005; 19:1779-1787.
7. Kelly WK, Rlchon VM1 O'Connor O1 et al. Phase I clinical trial of histone deacetylase inhibitor: suberoy- lanilide hydroxamic acid administered intravenously. Clin. Cancer Res 2003;9:3578-3588.
8. Owens IS1 Ritter JK. Gene structure at the human UGTI locus creates diversity in. isozyme structure, substrate specificity, and regulation. Prog Nucleic Acid Res MoI Biol 1995;51:305-338
9. Ren Q, Murphy SE, Zheng Z, Lazarus P. O- Glucuronidation of the lung carcinogen 4-(methyl- nitrosamino)-!- (3-pyridyl)-l-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 2000;28:1352-1360.
10. Tukey RH, Strassburg CP. Human UDP-glucuronosyl- transferases: metabolism, expression, and disease. Annu Rev Pharmacol. Toxicol. 2000;40:581-616.
11. Mackenzie PI, Walter Bock K, Burchell B, et al. Nomenclature update for the mammalian UDP glyco- syltransferase (UGT) gene superfamily. Pharm.acogen.et Genomics 2005:15:677-85.
12. Nagar S, Remmel RP. Uridine diphosphoglucurono- syltransferase pharmacogenetics and cancer. Oncogene 2006;25:1659-1672.
13. Liu CY, Chen PM, Chiou TJ, et al. UGT1A1»28 polymorphism predicts irinotecan-induced severe tox- icities without affecting treatment outcome and survival in. patients with metastatic colorectal carcinoma. Cancer 2008;112:1932-1940.
14. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez- Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetics pharmacoepige- netic and clinical aspects. Phannacol Ther 2007:116: 496-526.
15. Araki J, Kobayashi Y, Iwasa M, et al. Polymorphism of UDP-glucuronosyltransferase IA7 gene: a possible new risk factor for lung cancer. Eur J Cancer 2005:41:2360-2365.
16. Burchell B, Hume R. Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol 1999;14: 960-966.
17. Zheng Z, Fang JL, Lazarus P. Glucuronidation: an important mechanism for detoxification of benzo[a]py- rene metabolites in aerodigestlve tract tissues. Drug Metab Dispos 2002;30:397-403.
18. Gallagher CJ, Muscat JE, Hicks AN, et al. The UDP-glucuronosyltransferase 2B17 gene deletion poly- morphism: sex-specific association with urinary 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanol glucuro- nidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev 2007;16:823-828.
19. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan tox- icity: a pharmacogenetic analysis. Cancer Res 2000:60: 6921-6926
20. Haaz MC, Rivory L, Jantet S, Ratanasavanh D, Robert J. Glucuronidation of SN-38, the active metabolite of irinotecan, by human, hepatic microsomes. Pharmacol Toxicol 1997;80:91-96.
21. Ramchandani RP, Wang Y, Booth BP, et al. The role of SN-38 exposure, UGT1A1"28 polymorphism, and base- line bilirubin level, in predicting severe irinotecan toxicity. J Clin Pharmacol.2007;47:78-86.
22. Blevins-Primeau AS, Sun D, Chen G, et al. Functional significance of UDP-glucuronosyltransferase variants In the metabolism of active tamoxifen metabolites. Cancer Res 2009;69:1892-1900.
23. Court MH, Krishnaswamy S, Hao Q, et al. Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 2003;31:1125-1133.
24. Wiener D, Doerge DR, Fang JL, Upadhyaya P, Lazarus P. Characterization of N-glucuronldation of the lung carcinogen 4-(m.ethylnitrosamin.o)-l-(3-pyr- idyl)-l-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1.A4. Drug Mètab Dispos 2004;32:72-9.
25. Coughtrie MW, Burchell B, Bend JR. A general assay for UDPglucuronosyltransferase activity using polar amino-cyano stationary phase HPLC and UDP[U-14C]glucuronic acid. Anal Biochem. 1986;159: 198-205.
26. Sun D, Sharma AK, Dellinger RW, et al. Glucuroni- dation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 2007; 35:2006-2014.
27. Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, Lazarus P. Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase IAlO. Carcinogenesis 2007;28:2412-2418.
28. Chen G, Dellinger RW, Sun D1 Spratt TE1 Lazarus P. Glucuronidation of tobacco-specific nitrosamines by UGT2B10. Drug Metab Dispos 2008;36:824-830.
29. Dellinger RW1 Fang JL1 Chen G1 Weinberg R1 Lazarus P. Importance of UDP-glucuronosyltransferase IAlO (UGTlAlO) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGTlA10139Lys isoform. Drug Metab Dispos 2006;34: 943-949.
30. Fang JL1 Beland FA1 Doerge DR1 et al. Characteriza- tion, of benzo(a)pyren.e-trans-7,8-dihydrodiol glucuroni- dation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res 2002; 62:1978-1986.
31. Upadhyaya P1 Kenney PM1 Hochalter JB1 Wang M, Hecht SS. Tumorigeniclty and metabolism of 4-(m.eth- yln.itrosamino)-I-(3-pyridyl)-l-butano.l enantiomers and metabolites in the A/J mouse. Carcinogenesis 1999;20: 1577-1582.
32. Lazarus P1 Zheng Y1 Aaron Runkle E1 Muscat JE1 Wiener D. Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genomics 2005:15:769-778.
33. Ramalingam SS1 Parise RA1 Ramananthan RK1 et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclltaxel for advanced solid malignan- cies. Clin Cancer Res 2007;13:3605-3610.
34. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P. Characterization, of tamoxifen and 4- hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 2006;8:R50.
35. Parise RA, Holleran JL, Beumer JH1 Ramalingam. S1 Egorin. MJ. A liquid chromatography-electrospray ioni- zation, tandem mass spectrometry assay for quantita- tion of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metab- olites in human serum. J Chromatogr B Analyt Techno! Biomed Life Sei 2006;840:108-115.
36. Gulllemette C, Ritter JK, Auyeung DJ, Kessler FK1 Housman DE. Structural heterogeneity at the UDP- glucuronosyltransferase I locus: functional consequen- ces of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 2000;10:629-644.
37. Huang YH1 Galijatovic A1 Nguyen. N1 et al. Identifica- tion and functional characterization of UDP-glucurono- syltransferases UGTIA8*1, UGT1A8"2 and UGTlAS11S. Pharmacogenetics 2002;12:287-97.
38. Elahi A, Bendaly J, Zheng Z, et al. Detection of UGTlAlO polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 2003:98:872-880.
39. Miirata M1 Warren EH1 Riddell SR. A human minor histocompatibility antigen resulting from differential expression, due to a gene deletion. J Exp Med 2003:197:.1279-89.
40. Wilson W III, Pardo-Manuel de Villena F1 Lyn-Cook BD1 et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004;84:707-14.
41. Ohno S1 Nakajin S. Determination of mRNA expres- sion of human UGTs and application, for localization in various human tissues by real time RT-PCR. Drug Metab Dispos 2008:37:32-40.
42. Strassburg CP1 Strassburg A1 Nguyen N1 Li Q1 Manns MP1 Tukey RH. Regulation and function of family I and family 2 UDP-glucuronosyltransferase genes (UGTlA1 UGT2B) in human oesophagus. Biochem. J 1999:338:489-498.
43. Nakamura A1 Nakajima M1 Yamanaka H1 Fujlwara R1 Yokoi T. Expression of UGTlA and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 2008;36:1461-1464.
44. Darbari DS1 van Schalk RH1 Capparelli EV1 Rana S1 McCarter R1 van. den. Anker J. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine In patients with sickle cell disease. Am, J Hematol 2008;83:200-202.
45. Bosnia PJ1 Chowdhury JR1 Bakker C1 et al. The genetic basis of the reduced expression, of bilirubin UDP- glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-1175.
46. Iolascon A, Faienza MF1 Centra M1 Store.1.11 S1 Zelante L1 Savoia A. (TA)8 allele in the UGTlAl gene promoter of a Caucasian with Gilbert's syndrome. Haematologica 1999:84:106-109.
47. Paoluzzi L1 Singh AS1 Price DK1 et al. Influence of genetic variants in UGTlAI and UGT1.A9 on the in vivo glucuronidation of SN-38. J Clin. Pharmacol 2004;44:854-60.
48. Iyer L1 Hall. D1 Das S1 et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGTlAI promoter polymorphism. Clin Pharmacol Ther 1999;65:576-582.
49. Hosklns JM1 Goldberg RM1 Qu P1 Ibrahim, JG1 McLeod HL. UGT.lAr28 genotype and irinotecan- induced neutropenia: dose matters. J Natl Cancer Inst 2007;99:1290-1295.
50. Chen G1 Dellinger RW1 Gallagher CJ1 Sun D, Lazarus P. Identification of a prevalent functional missense polymorphism in. the UGT2B10 gene and its associ- ation with UGT2B10 inactivation against tobacco- specific nitrosamines. Pharmacogenet Genomics 2008; 18:181-191.
51. Vansteenklste J1 Van. Cutsem E1 Dumez H1 et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 2008;26:483-488.
52. Fantin VR, Richon. VM. Mechanisms of resistance to histone deacetylase Inhibitors and their therapeutic implications. Clin Cancer Res 2007;13:7237-7242.
53. Turgeon D, Carrier JS, Chouinard S, Belanger A. Glucuronidation activity of the UGT2BI7 enzyme toward xenobiotics. Drug Metab Dispos 2003;31:670-676.
54. Swanson C, Mellstrom D1 Lorentzon M1 et al. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucur- onidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab 2007;92:4878-4882.
55. Yang TL1 Chen XD1 Guo Y1 et al. Genome-wide copy- number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet 2008;83: 663-674.